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Interleukin 2 regulates its own receptors
(T cells/cell growth/hormone receptors/receptor turnover/hormone autoregulation)
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The Department of Medicine, Dartmouth Medical School, Hanover, NH 03756

Communicated by Walter H. Stockmayer, October 4, 1984

concentrations of IL-2 (6). Accordingly, the T-cell IL-2 hormone-receptor system is a distinctive example of a hormone-receptor mechanism, as it appears to be under the
sole direction of signals that enter from the environment;
thus far, there is no evidence for internal feedback regulatory controls that enhance or diminish the antigen-initiated,
IL-2-dependent T-cell proliferative response.
The dissection and identification of the variables controlling T-cell growth that led to the present model was made
possible by the painstaking acquisition of unique cellular and
molecular reagents, including (i) synchronized IL-2 receptor'
clonal T-cell populations (6, 8), (ii) homogeneous immunoaffinity-purified IL-2 (10), (iii) the development of a quantitative radiolabeled IL-2 binding assay (5), and (iv) the identification of a monoclonal antibody reactive with IL-2 receptors
(anti-Tac) (9). Cytofluorographic studies utilizing anti-Tac
were especially revealing, since for the first time, it was discovered that IL-2 receptors have a logarithmic-normal distribution, not only within asynchronously proliferating polyclonal cell populations (7) but also within cloned and synchronized T-cell populations as well (7, 8). However, even
through functional (9) and biochemical studies (11-13) indicated that anti-Tac reacted with IL-2 receptors, quantitative
differences were found between the Tac antigen and IL-2
receptor densities (11-13), thus raising the possibility that
the epitope recognized by anti-Tac did not include the IL-2
binding site. Accordingly, several fresh experimental approaches were undertaken to compare the binding of radiolabeled IL-2 vs. anti-Tac to activated human T-cell populations. The results reveal that IL-2 binding sites and anti-Tacreactive epitopes differ markedly in their respective
turnover characteristics; moreover, IL-2 actually regulates
the expression of IL-2 receptor molecules as detected by radiolabeled IL-2 and anti-Tac binding. The IL-2-receptor interaction serves to diminish the density of high-affinity IL-2
receptors, at the very time it augments considerably Tac
antigen expression. Consequently, IL-2 governs the magnitude of its own biologic response by a unique mechanism,
manifested by an IL-2-promoted diminished expression of
IL-2 binding sites, and an increased expression of IL-2 receptor molecules that are recognized by anti-Tac but do not
bind IL-2 with high affinity.

The cell surface density of high-affinity
ABSTRACT
membrane receptors for the T-lymphocytotrophic hormone interleukin 2 (IL-2) determines the rate of T-cell-cycle progression. Since 10-fold greater numbers of IL-2 receptor molecules
were found by using a radiolabeled monoclonal antibody reactive with IL-2 receptors (anti-Tac) compared with binding of
IL-2, the functional relationship of the binding sites recognized
by both of these ligands was assessed. In the presence of cycloheximide, IL-2 binding sites declined with a half-time (to) of
2.6 hr, whereas the decay of anti-Tac binding sites was much
slower (t½ = 6.4 hr). Moreover, after limited membrane proteolysis, the half-time for the reappearance of IL-2 binding sites
was remarkably similar to its decay (1½ = 2.2 hr), while Tac
antigen reappearance was markedly retarded, returning to
only 20% of original levels within 5 hr after proteolysis. Addition of homogeneous immunoaffinity-purified IL-2 to cell populations that expressed equivalent IL-2 and anti-Tac binding
sites resulted in a time- and temperature-dependent 8- to 10fold enhancement of Tac epitope expression and, simultaneously, a 20-30% diminishment of detectable high-affinity
IL-2 binding sites. As the magnitude of the IL-2-dependent
proliferative response correlated with the density of high-affinity IL-2 binding sites, rather than Tac antigen levels, quantitation of Tac epitope density does not provide a reliable indication of IL-2 responsiveness among activated T-cell populations. Instead, IL-2-receptor interactions actually promote
the loss of IL-2 responsiveness by diminishing the density of
high-affinity binding sites at the time that Tac antigen levels
are increased.
T lymphocyte DNA replication and mitosis is determined by
a critical threshold of signals generated by the interaction
between interleukin 2 (IL-2) (1-4) and its specific membrane
receptors (5-7). Compared with other hormone-receptor
systems, the IL-2-T-cell system is exceptional; T cells do
not express IL-2 receptors unless activated by immunostimulatory ligands such as antigens, T-cell-specific monoclonal
antibodies, mitogenic lectins, and phorbol esters, all of
which trigger components of the T-cell surface antigen-receptor complex (4, 8). Moreover, once a cell population is
exposed to these agents, individual cells express IL-2 receptors at different rates, giving rise to the asynchronous entry
of cells into the proliferative phases of the cell cycle (6). If
IL-2 is excluded from an antigen-activated T-cell population,
IL-2 receptor expression still occurs, but DNA synthesis
does not proceed, since it is the IL-2-receptor interaction
that provides the crucial signal for initiation of DNA replication (6, 9). Furthermore, as IL-2 receptor expression is antigen-dependent, upon removal of the immunostimulatory signal, IL-2 receptor levels decline progressively. The proliferative rate of the cell population slows in parallel, and all of
the cells eventually reaccumulate in the resting (Go/GO)
phase of the cell cycle, even in the presence of saturating

MATERIALS AND METHODS
Cell Cultures. Human peripheral blood mononuclear cells
(PBM cells), isolated by Ficoll-Hypaque discontinuous gradient centrifugation, were cultured (1 x 106 cells per ml) in
RPMI 1640 medium (GIBCO) supplemented with 10% heatinactivated (560C, 45 min) fetal calf serum (FCS, Sterile Systems, Logan, UT) in the presence of

phytohemagglutinin

Abbreviations: IL-2, interleukin 2; anti-Tac, monoclonal antibody
reactive with the IL-2 receptor; FCS, heat-inactivated fetal calf serum; PBM cells, human peripheral blood mononuclear cells; PBt2,
phorbol 12,13-dibutyrate; PHA, phytohemagglutinin; EGF, epidermal growth factor.
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(PHA, 1 Ag/ml, Wellcome) for 72 hr to ensure IL-2 receptor
expression as described (6, 7). IL-2-dependent growth was
maintained at cell concentrations between 1 x 105 and 1 x
106 cells per ml by re-exposure to PHA (0.5 Ag/ml, 1 hr) at
10- to 14-day intervals and by supplementation with IL-2 every 2 days so that the IL-2 concentration was maintained at
.100 pM. To ensure IL-2 receptor re-expression by Go/Gj
synchronized cell populations in the absence of IL-2 production, phorbol 12,13-dibutyrate (PBt2, 50 ng/ml, 6 hr, Consolidated Midland, Brewster, NY) was used as the immunostimulatory agent, since PBt2 leads to IL-2 receptor reexpression without IL-2 production, as monitored by the IL2 bioassay (sensitivity, 1 pM) and by [3H]dThd incorporation
of the PBt2 stimulated cell population (unpublished observations).
[3H]dThd incorporation was monitored (1 hr, 2.0 ACi/ml,
specific activity = 1.9 Ci/mmol; 1 Ci = 37 GBq; Schwartz/
Mann) by precipitation onto glass fiber filter paper followed
by liquid scintillation spectroscopy.
IL-2 and Anti-Tac Binding Assays. Unlabeled and radiolabeled (with [3H]leucine and [3H]lysine) IL-2 derived from
JURKAT T-leukemia cells was purified from culture media
by immunoaffinity adsorption using a monoclonal antibody
reactive with IL-2 (DMS-3) as described (6, 10). Both preparations were homogeneous within the limits of detection by
NaDodSO4/polyacrylamide gel electrophoresis, reversedphase HPLC, and amino acid sequence analysis (6, 10). The
specific activity of [3H]IL-2 was 9.4 x 104 dpm/pmol. AntiTac monoclonal antibodies were purified from ascitic fluid
by protein A-Sepharose (Sigma) affinity adsorption (10) and
radiolabeled using Enzymobeads (Bio-Rad) (specific activity
4.0 x 105 dpm/pmol).
To accurately quantitate ligand binding, especially on cells
exposed to IL-2, any receptor-bound IL-2 was dissociated
by a 60-sec exposure to RPMI 1640 medium/25 mM sodium
acetate, pH 4.0, followed by three washes with cold (4°C)
RPMI 1640 medium/10% FCS. For equilibrium binding analysis, serial dilutions of [3H]IL-2 or 125I-labeled anti-Tac (125I1
anti-Tac) were incubated with 1-10 x 105 cells (200 ,ul) for 20
min at 37°C or 60 min at 4°C. Cell-bound and free radioactivity was determined after separation by centrifugation (13,000
x g, 90 sec) through a mixture of 84% silicone oil and 16%
paraffin oil as described (5, 6). The number of binding sites
per cell was determined by Scatchard analysis after subtraction of nonsaturable binding, as detected in the presence of a
150-fold molar excess of unlabeled ligand.
IL-2 Receptor Turnover Characteristics. To ascertain the

contribution of protein synthesis to membrane levels of IL-2
receptors and Tac antigen, IL-2 receptor' cells were harvested, maintained in IL-2-free conditions for 4-6 hr to allow
dissociation of endogenously bound IL-2, and incubated
without IL-2 supplementation (to study turnover in the absence of ligand) at 37°C in RPMI 1640 medium/10% FCS
either in the presence or absence of 0.5 mM cycloheximide
(Sigma). The levels of IL-2 and anti-Tac binding sites were
determined at various intervals.
To establish the characteristics of renewal of IL-2 and
anti-Tac binding sites following Pronase treatment, the same
IL-2 receptor' cell populations were incubated at 37°C for
30 min in the presence and absence of Pronase (200 Mg/ml,
Sigma), then washed three times with cold (4°C) RPMI 1640
medium/10% FCS, and replaced in culture (1 x 106 cells per
ml) without exogenous IL-2. Here too, the levels of IL-2 and
anti-Tac binding sites were determined at various time intervals.

RESULTS
IL-2 Receptor Turnover Characteristics. The turnover of

membrane proteins, generally determined by the half-time
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for disappearance or appearance of a population of molecules, is equivalent to their median functional lifetime (14).
Therefore, to investigate what was perceived as a subtle relationship between the binding sites for IL-2 and for antiTac, the turnover characteristics for the sites recognized by
these ligands were assessed in the absence of IL-2. Lectinactivated IL-2 receptor' human peripheral T cells were examined for decay of [3H]IL-2 and for 125I-anti-Tac binding in
the presence of cycloheximide. Simultaneously, the kinetics
of reappearance of binding capacity was studied subsequent
to limited membrane proteolysis. The results of six experiments, performed in the absence of exogenous IL-2, are illustrated in Fig. 1; the findings reveal that IL-2 binding sites
and Tac antigen manifest markedly different turnover characteristics. IL-2 binding declined rapidly in the presence of
cycloheximide: receptor density was reduced by 50o within
2.6 hr, and only 30% of original levels remained after 5 hr. In
contrast, Tac antigen density, which was 10-fold greater than
IL-2 receptor density at the beginning of the experiments,
persisted at >90% of original levels for 3 hr, and by 5 hr had
only decreased gradually to 70% (Fig. 1A). It is noteworthy
that these decay characteristics were mirrored by the kinetics of reappearance of binding capacity following limited
membrane proteolysis (Fig. 1B). IL-2 receptor density returned to 50% of control levels by 2.2 hr and attained 90% of
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FIG. 1. IL-2-independent disappearance and reappearance of
binding sites for IL-2 and anti-Tac. Human PHA-activated (72 hr)
IL-2 receptor' T cells were examined for [3H]IL-2 (e) and 125I-antiTac (o) binding in the presence of cycloheximide (A) and after limited membrane proteolysis (B). The data are presented as the percent
of IL-2 and anti-Tac binding sites compared to control cells cultured
in medium alone. Symbols represent the mean ± SEM of six separate experiments in which the maximal levels of IL-2 receptors and
anti-Tac binding sites at t = 0 were 5813 ± 648 and 59,000 ± 19,000,
respectively. The recovery of IL-2 and anti-Tac reactivity following
Pronase treatment was inhibited by cycloheximide (data not shown),
indicating that receptor renewal required de novo synthesis of protein.
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the original levels by 5 hr, whereas the reappearance of antiTac binding remained markedly retarded, reaching only 20%
of pretreatment levels during this interval. Especially enlightening are the half-times (t½) for the decay and reappearance of IL-2 and anti-Tac binding derived from these data.
Although the half-times required for the decline and reappearance of IL-2 binding sites are similar (2.6 hr and 2.2 hr,
respectively), the values for the decline and reappearance of
anti-Tac binding, obtained by extrapolation from the plots,
proved to be much longer and, moreover, discordant: the
decay of Tac antigen is slower by a factor of 2.5 than IL-2
binding (t;½ = 6.4 hr), and its reappearance is prolonged inordinately compared either to its decay or the kinetics of reappearance of IL-2 binding. Although the theoretical half-time
for Tac antigen reappearance extrapolated from the plot is
14.2 hr, the density of anti-Tac binding sites was observed to
plateau 5 hr after proteolysis and to actually decline over the
succeeding 12 hr. Thus, as a consequence of the 10-fold discrepancy between Tac antigen and IL-2 binding site levels
prior to proteolysis, 8-10 hr after enzyme exposure the absolute levels of IL-2 binding sites and Tac antigen are equivalent, provided the cells have not been supplemented with IL2.
Effect of IL-2 on Expression of IL-2 Receptors and Tac
Antigen. In previous studies, IL-2 receptor and Tac antigen
expression had been found to be dependent upon lectin or
antigen stimulation and proved to be transient in nature:
upon removal of the immunostimulatory signals, IL-2 receptor levels decline progressively (6, 8). Consequently, in view
of the marked difference between the turnover characteristics for anti-Tac and IL-2 binding sites, especially the slow
decay and reappearance of Tac antigen, it became essential
to ascertain IL-2 receptor and Tac antigen expression sequentially following removal of the receptor-inducing signal
provided by lectin. IL-2 receptor' T cells harvested after 3
days of culture were washed and replaced in culture with a
saturating concentration of immunoaffinity-purified homogeneous IL-2 (500 pM) (10). Cells cultured with IL-2 were
maintained in exponential growth at cell concentrations between 1 x 105 and 1 x 106 cells per ml by replacement of IL2 every 2 days; control cells, cultured without IL-2, were
washed every 2 days and the medium was replaced. To
quantitate accurately the IL-2 binding sites on cells cultured
with IL-2, residual membrane-bound IL-2 was eluted by
brief exposure to acid (pH 4.0, 60 sec), a procedure found to
remove .95% of receptor-associated IL-2. The results of
this approach, given in Fig. 2, reveal a striking paradox of
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FIG. 2. Effect of IL-2 on the decline of binding sites for IL-2 and
for anti-Tac after removal of lectin. PHA-stimulated (72 hr) human
PBM cells were harvested, washed, and replaced into culture in
fresh medium with receptor-saturating concentrations of affinity-purified IL-2 (500 pM). (A) IL-2 binding sites per cell in the presence
(e) and absence (o) of exogenous IL-2. (B) Anti-Tac binding sites
per cell in the presence (e) and absence (o) of exogenous IL-2.
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Table 1. Inverse effect of IL-2 on IL-2 receptor vs. Tac antigen
expression after PBt2 stimulation

[3H]dThd
incorporation,

IL-2 binding
Anti-Tac binding
IL-2
cpm
sites per cell
sites per cell
Without
527 ± 148
7185 ± 1184
8,934 ± 2437
With
3139 ± 294
5050 ± 472
41,502 ± 2960
Data shown represent the mean ± SEM of six separate experiments after both primary and secondary (11 days) activation of
human PBM cells by PBt2. In three primary stimulation experiments, freshly isolated PBM cells were cultured with 50 ng of PBt2
per ml in the presence of affinity-purified IL-2 (500 pM) for 72 hr
prior to the binding assay. In three secondary stimulation experiments, binding assays were performed after 24 hr of culture with or
without IL-2, the time required for maximal receptor expression
after a secondary stimulation (6). [3H]dThd data are expressed as
cpm per 104 cells ± SEM.

IL-2 receptor and Tac antigen expression that was already
evident within 24 hr of culture (day 4). Cells cultured in the
presence of IL-2 expressed 20% fewer IL-2 binding sites
than those deprived of IL-2 (6000 sites per cell vs. 7500 sites
per cell) (Fig. 2A) but expressed more than twice the density
of anti-Tac binding sites compared to cells cultured without
IL-2 (96,000 sites per cell vs. 42,500 sites per cell) (Fig. 2B).
Thus, IL-2-receptor interaction functioned to diminish IL-2
binding sites even as it enhanced the magnitude of Tac antigen expression. Subsequently, in the 6 days of culture after
removing the immunostimulatory signal provided by lectin,
both IL-2 and anti-Tac binding sites declined progressively,
although the cell population exposed to IL-2 lost IL-2 binding sites more rapidly but retained Tac binding sites longer
than the cell population cultured without IL-2.
To determine the effect of IL-2 on the acquisition of IL-2
receptors and Tac antigen, lymphocytes were activated with
PBt2 an agent that stimulates IL-2 receptor expression in the
absence of IL-2 production (unpublished). This made it feasible to supply IL-2 exogenously; its effect on IL-2 receptor
and Tac antigen densities could then be measured at the precise time of maximal receptor expression. As is evident in
Table 1, the results of six experiments attest to the magnitude of the difference between Tac antigen density and IL-2
receptor density being attributable to IL-2. Accordingly, in
the absence of exogenous IL-2, PBt2-activated cells incorporated low levels of [3H]dThd but expressed equivalent levels
of IL-2 and Tac antigen binding sites. In contrast, cells supplemented with IL-2 proliferated but expressed 30o fewer
IL-2 binding sites and 5-fold higher densities of Tac antigen
compared to control cell populations.
To investigate the time course and the effect of temperature on the IL-2 augmentation of Tac epitope expression,
Go/Gj synchronized, IL-2 receptor' cells were exposed to
IL-2 at 40C and at 370C. No change in IL-2 or anti-Tac binding occurred within 3 hr at 4°C. Rather, the enhancement of
Tac epitope expression required 37°C and became evident
slowly over 24 hr (Fig. 3). Thus, as these differences precede
the onset of cellular division (6-8), the reciprocal switch in
IL-2 receptor expression is not attributable to proliferative
changes in the cell population over this time interval. Moreover, an apparent change in Tac epitope and IL-2 binding
affinity is also excluded: the equilibrium dissociation constants of both ligands remained unchanged before and after
the IL-2 induced switch in IL-2 receptor expression (Fig. 3
Insets).
T-Celi Proliferation and IL-2 Receptor vs. Tac Antigen Density. Although previous studies have established that the extent of IL-2-mediated T-cell proliferation was dictated by the
affinity and density of IL-2 receptors (5-8), the discovery
that IL-2 induces a marked enhancement of the density of
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enhancement of the IL-2 response, this despite large differences between the Tac antigen:IL-2 receptor ratios of the
cell populations. Maximal levels of [3H]dThd incorporation
and the IL-2 concentration required for a half-maximal proliferative response proved to be similar, thus corresponding
to the equivalent densities of high-affinity IL-2 receptors
rather than to Tac antigen levels.
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FIG. 3. IL-2 enhancement of Tac epitope and diminution of IL-2
binding site expression. PHA-activated (72 hr) T cells were harvested from IL-2-dependent cell growth after 11 days of culture,
washed, and maintained in IL-2-free medium for 24 hr. Re-expression of IL-2 receptors was ensured by exposure to PBt2 (50 ng/ml, 6
hr). Thereafter, the cells were cultured with or without IL-2 (500
pM) for 24 hr and anti-Tac binding was determined at the times indicated on cells cultured in the presence (e) and absence (a) of IL-2.
(Inset A) Scatchard plots of [3H]IL-2 binding performed after 24 hr
in the presence (e, Kd = 21 pM, 2800 sites per cell) and absence (0,
Kd = 23 pM, 4400 sites per cell) of IL-2. (Inset B) Scatchard plots of
125I-anti-Tac binding performed after 24 hr in the presence (a, Kd =
0.3 nM, 43,000 sites per cell) and absence (0, Kd = 0.3 nM, 10,000
sites per cell) of IL-2. B/F, bound/free.

Tac epitopes led to a reassessment of the apparent correlation between IL-2 receptor levels and the T-cell proliferative
response, particularly in relationship to Tac antigen levels.
To compare cell populations with a high and low Tac antigen:IL-2 receptor ratio, IL-2 receptor' T cells cultured with
IL-2 for short (4 days) or prolonged (40 days) periods were
subjected to limited proteolysis to remove both IL-2 receptors and Tac antigen. After an 8-hr equilibration period to
facilitate recovery and equivalent expression of IL-2 and Tac
antigen binding sites, these cell populations were monitored
for their IL-2 concentration-dependent proliferative response and compared with untreated cells, which expressed
a high Tac antigen:IL-2 receptor ratio. The results, given in
Table 2, indicate that a high Tac antigen density on IL-2 receptor' T cells does not lead to any discernible suppression or

The results from the various experimental approaches devised for this investigation all lead to the conclusion that the
magnitude of Tac epitope expression is dependent upon the
interaction of IL-2 with high-affinity IL-2 binding sites. Consequently, the IL-2-induced variability of Tac antigen:IL-2
receptor ratios, and the absence of correlation between Tac
antigen density and IL-2-promoted T-cell proliferation, in effect obviate Tac antigen quantitation as a physiologically
pertinent indicator of IL-2 receptor density or IL-2 responsiveness among T-cell populations. For the present, the
functional significance of the IL-2-induced expression of the
new anti-Tac reactive molecules that do not bind IL-2 with
high affinity remains obscure. From the results obtained
thus far, a high density of Tac epitopes does not alter the
magnitude of the IL-2-mediated proliferative response, provided adequate levels of high-affinity receptors are present.
However, it is conceivable that the newly expressed molecules play a role unrelated to T-cell growth and are associated with differentiative aspects of T-cell function. If so, the
newly expressed molecules may interact with a separate
lymphokine, analogous but not identical to IL-2. In this regard, unpublished results indicate that the IL-2-induced,
newly expressed Tac antigen' molecules can still bind IL-2,
albeit with much lower affinity.
The most compelling observation emerging from these
studies is the reciprocal effect on the expression of high-affinity, biologically relevant IL-2 binding sites mediated by
immunostimulatory signals-e.g., antigen or lectin-and
that of IL-2 itself. Triggering of the T-cell antigen-receptor
complex results in the expression solely of high-affinity IL-2
binding sites, whereas IL-2 binding to these very same highaffinity sites results in a marked change in the IL-2 receptor
molecules expressed. Further studies will determine whether the IL-2-promoted decrease in detectable high-affinity IL2 binding sites results from the combination of the induction
of new molecules that are incapable of binding IL-2 with the
same high affinity, in addition to an IL-2-promoted accelerated internalization and degradation of cell surface high-affinity binding sites. However, the marked IL-2-induction of
Tac antigen expression indicates that an IL-2-promoted

Table 2. IL-2 proliferative effect on cell populations expressing different Tac antigen:IL-2
receptor ratios
Tac antigen
IL-2 receptor
Maximal
IL-2
Pronase
Experiment
sites per cell
sites per cell
Ratio*
[3]dThd
ED50, pM
1
With
14,465
10,021
1.4:1
7633
14
Without
64,255
10,052
6.4:1
8677
11
2
With
11,959
14,357
0.8:1
4410
17
Without
81,340
11,536
7.1:1
5162
20
Data shown represent IL-2 and anti-Tac binding sites per cell, as determined by Scatchard analysis
performed on short-term (4 days, experiment 1) and long-term (40 days, experiment 2) cultured cells
with and without Pronase treatment and an 8-hr equilibration period. The IL-2 concentrationdependent proliferative responses were determined by [3H]dThd incorporation during the last 4 hr of
an 18-hr culture (3 x 104 cells) after subtraction of values obtained in the absence of IL-2. Each cell
population gave a typical sigmoid logarithmic dose-response to IL-2; the concentration of IL-2 that
yielded 50% of the maximal [3H]dThd incorporation of each population was determined by probit
analysis using a homogeneous immunoaffinity-purified standard IL-2 preparation of known protein
concentration.
*Tac antigen: IL-2 receptor ratio.
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switch to the appearance of new, low-affinity receptor molecules is a previously unrecognized phenomenon that could
contribute to the apparent disappearance of detectable highaffinity IL-2 binding sites. In this regard, were it not for the
singular Pature of the anti-Tac reactivity, the IL-2-induced
change in IL-2 receptor expression would have remained undetected: indeed, there would have been no reason to suspect an induction in the expression of different receptor molecules. Thus, the absence of evidence for a similar mechanism operative in other hormone-receptor systems could be
due to the lack of application of additional methods of receptor detection other than ligand binding.
It may well be significant that two classes of receptors
have been demonstrated in other growth-promoting polypeptide hormone systems, including epidermal growth factor
(EGF) (15) and nerve growth factor (16, 17). Since the biologically relevant receptor in both of these systems has been
thought to be embodied in the binding site with the highest
affinity, studies of receptor turnover and ligand-associated
changes in levels of receptor expression have focused exclusively on the high-affinity sites. Consequently, receptor
turnover data are not available for the second class of receptors in these systems. Thus, the importance of the T-cell IL2 hormone-receptor studies resides in the probability that
growth factor-mediated reciprocal changes in receptor
expression could be a general phenomenon, which is likely
to become evident only when both classes of receptors are
quantitated after ligand binding. Also, information regarding
the mechanism by which the ligand-receptor interaction
promotes a switch in receptor expression should be forthcoming from investigations of receptor gene expression. Recent studies have shown that there are two IL-2 receptor
mRNA transcripts that arise from one gene (18, 19). Accordingly, all of the present findings are explicable on the basis
that only one of the two transcripts translates molecules containing a high-affinity IL-2 binding site, whereas both transcripts encode receptor molecules that express the Tac epitope. For purposes of comparison, the EGF receptor gene is
the only other polypeptide hormone receptor that has been
cloned (20). Thus, it is especially germane that normal EGF
receptor+ cells also contain one EGF receptor gene, contain
two mRNA transcripts, and express two classes of receptors
for EGF (15, 20). In both the IL-2 and EGF systems, quantitative binding assays have yet to be performed using cells
transfected with cDNAs corresponding to each of the two
receptor transcripts. Consequently, the construction of stable, high-expression transfectants now becomes a key requirement for further, more directed analyses of the implied
structural and functional relationship of both receptor
mRNA transcripts and their translation products.
Regardless of the precise mechanism responsible for the
variable nature of IL-2 receptors expressed, the present
findings lead to an inescapable conclusion that the intracellular signals generated by triggered antigen receptors and triggered IL-2 receptors function to switch membrane IL-2 receptor expression in a reciprocal fashion. Accordingly, there
is a critical interplay between the positive effect of antigen
receptor triggering and the negative influence of IL-2 receptor triggering, both harmonizing to regulate precisely the
density of high-affinity IL-2 binding sites, and thereby determine the ultimate proliferative potential of activated T cells.

Proc. NatL Acad. Sci. USA 82

(1985)

The immunologic consequences of such reciprocal regulation are profound; it offers all of the requisite attributes for
providing an elegant fail-safe form of intrinsic control over
antigen-initiated, but IL-2-dependent, T-cell clonal expansion. Since high-affinity IL-2 receptors are expressed only
upon antigen receptor activation, and as antigen is cleared
progressively in vivo, the IL-2 receptor-mediated switch in
IL-2 receptor expression inevitably favors the loss of IL-2
binding sites and regression to a resting Go cell.
Having perceived thy remarkable functional implications
of such a regulatory system, it is considered likely that this
constitutes a basic means by which hormones regulate the
level of their receptors and, in this distinctive fashion, exercise strict control over their own biologic responses.
We thank Dr. T. Uchiyama for his generous supply of the anti-Tac
monoclonal antibody, Dr. M. Landy for editorial comments, and
Drs. T. Nikaido, J. Yodoi, and T. Honjo for sharing the results of
their studies on the IL-2 receptor cDNA clones prior to submission
for publication. This research was supported in part by Grants CA17643, CA-17323, CA-23108, and CA-26273 from The National Cancer Institute.
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